Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Others
    (1)
Filter
Search Result
Results for "

1310746-17-8

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    5
    TargetMol | Activity
Infigratinib acetate
T710021310746-17-8
Infigratinib acetate, also known as, BGJ398 acetate or NVP-BGJ398 acetate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib acetate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.
  • Inquiry Price
1-2 weeks
Size
QTY
Infigratinib monohydrate
T710041310746-11-2
Infigratinib monohydrate, also known as, BGJ398 monohydrate or NVP-BGJ398 monohydrate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib monohydrate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.
  • Inquiry Price
1-2 weeks
Size
QTY
Infigratinib phosphate
T163641310746-10-1
Infigratinib phosphate (BGJ-398 phosphate) is an effective inhibitor of the FGFR family (IC50: 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively).
  • Inquiry Price
6-8 weeks
Size
QTY
Infigratinib
T1975872511-34-7
Infigratinib (NVP-BGJ398) (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
Infigratinib mesylate
T710031310746-12-3
Infigratinib mesylate, also known as, BGJ398 mesylate or NVP-BGJ398 mesylate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib mesylate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.
  • Inquiry Price
1-2 weeks
Size
QTY